Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | CCR5 | P51681 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15358918 | 0.89 | MAPK1 (0.47) | MAPK1TSHRMEN1LMNAKMT2A | |
| SCHEMBL12277874 | 0.88 | KCNH2 (0.37) | MAPK1TSHRMEN1LMNAKMT2A | |
| SCHEMBL296886 | 0.86 | KCNH2 (0.42) | MEN1KMT2AKDM4EHPGDKCNH2 | |
| SCHEMBL15352415 | 0.86 | PRNP (0.41) | MAPK1KDM4EHPGDCNR2KCNH2 | |
| SCHEMBL13339581 | 0.85 | MAPK1 (0.44) | MAPK1TSHRMEN1LMNAKMT2A | |
| SCHEMBL15363361 | 0.85 | SLC6A4 (0.38) | MAPK1MEN1LMNAKMT2AL3MBTL1 | |
| SCHEMBL18796264 | 0.85 | SMN1; SMN2 (0.39) | MAPK1LMNAAMY1AKDM4EALDH1A1 | |
| SCHEMBL15358942 | 0.84 | MAPK1 (0.43) | MAPK1TSHRMEN1LMNAKMT2A | |
| SCHEMBL15359017 | 0.83 | MAPK1 (0.42) | MAPK1TSHRMEN1LMNAKMT2A | |
| SCHEMBL19330207 | 0.83 | KCNH2 (0.43) | L3MBTL1KCNH2CACNA1CCYP3A4GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617244-B2 | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-11 | — | — | US | disclosed |
| EP-1898910-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-28 | — | — | EP | disclosed |
| EP-2841426-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-28 | — | — | EP | disclosed |
| EP-2841425-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-23 | — | — | EP | disclosed |
| US-9133167-B2 | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-15 | — | — | US | disclosed |
| US-20150065502-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN-CILAG (FR) | 2015-03-05 | — | — | US | disclosed |
| EP-2841426-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2015-03-04 | — | — | EP | disclosed |
| EP-2841425-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051244-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN-CILAG (FR) | 2015-02-19 | — | — | US | disclosed |
| WO-2013160435-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-31 | — | — | WO | disclosed |
| US-20100029679-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN-CILAG (FR) | 2010-02-04 | — | — | US | disclosed |
| US-20100029679-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN-CILAG (FR) | 2010-02-04 | — | — | US | disclosed |
| CN-101547906-A | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-30 | — | — | CN | disclosed |
| EP-2099761-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008068266-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068268-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068272-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068272-A2 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| EP-1898910-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007000436-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065502-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | MAPK1 1488/4885CCR5 1579/4885TSHR 4624/4885 |
| US-20150051244-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB5, NDUFB7 | MAPK1 1488/4885CCR5 1579/4885TSHR 4624/4885 |
| US-20100029679-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | NQO2, NDUFB7, NDUFB5 | MAPK1 1328/4885CCR5 1784/4885TSHR 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.